Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry
<h4>Background</h4> Liver steatosis is often observed in chronic HCV infection and associated to genotype or comorbidities. NAFLD is an important risk factor for end-stage liver disease. We aimed to analyse the course of NAFLD as a concomitant disease in a cohort of HCV patients. <h4&...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203066/?tool=EBI |
| _version_ | 1811245179306246144 |
|---|---|
| author | Monika Rau Peter Buggisch Stefan Mauss Klaus H. W. Boeker Hartwig Klinker Tobias Müller Albrecht Stoehr Jörn M. Schattenberg Andreas Geier |
| author_facet | Monika Rau Peter Buggisch Stefan Mauss Klaus H. W. Boeker Hartwig Klinker Tobias Müller Albrecht Stoehr Jörn M. Schattenberg Andreas Geier |
| author_sort | Monika Rau |
| collection | DOAJ |
| description | <h4>Background</h4> Liver steatosis is often observed in chronic HCV infection and associated to genotype or comorbidities. NAFLD is an important risk factor for end-stage liver disease. We aimed to analyse the course of NAFLD as a concomitant disease in a cohort of HCV patients. <h4>Methods</h4> The German Hepatitis C-Registry is a national multicenter real-world cohort. In the current analysis, 8789 HCV patients were included and separated based on the presence of steatosis on ultrasound and/or histology. Fibrosis progression was assessed by transient elastography (TE), ultrasound or non-invasive surrogate scores. <h4>Results</h4> At the time of study inclusion 12.3% (n = 962) of HCV patients presented with steatosis (+S) (higher rate in GT-3). Diabetes mellitus was more frequent in GT-1 patients. HCV patients without steatosis (-S) had a slightly higher rate of fibrosis progression (FP) over time (30.3%) in contrast to HCV patients +S (26%). This effect was mainly observed in GT-3 patients (34.4% vs. 20.6%). A larger decrease of ALT, AST and GGT from baseline to FU-1 (4–24 weeks after EOT) was found in HCV patients (without FP) +S compared to -S. HCV patients -S and with FP presented more often metabolic comorbidities with a significantly higher BMI (+0.58kg/m2) compared to patients -S without FP. This was particularly pronounced in patients with abnormal ALT. <h4>Conclusion</h4> Clinically diagnosed steatosis in HCV patients does not seem to contribute to significant FP in this unique cohort. The low prevalence of steatosis could reflect a lower awareness of fatty liver in HCV patients, as patients -S and with FP presented more metabolic risk factors. |
| first_indexed | 2024-04-12T14:36:19Z |
| format | Article |
| id | doaj.art-90359d06943948ee940476a5a2874203 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T14:36:19Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-90359d06943948ee940476a5a28742032022-12-22T03:29:05ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01176Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-RegistryMonika RauPeter BuggischStefan MaussKlaus H. W. BoekerHartwig KlinkerTobias MüllerAlbrecht StoehrJörn M. SchattenbergAndreas Geier<h4>Background</h4> Liver steatosis is often observed in chronic HCV infection and associated to genotype or comorbidities. NAFLD is an important risk factor for end-stage liver disease. We aimed to analyse the course of NAFLD as a concomitant disease in a cohort of HCV patients. <h4>Methods</h4> The German Hepatitis C-Registry is a national multicenter real-world cohort. In the current analysis, 8789 HCV patients were included and separated based on the presence of steatosis on ultrasound and/or histology. Fibrosis progression was assessed by transient elastography (TE), ultrasound or non-invasive surrogate scores. <h4>Results</h4> At the time of study inclusion 12.3% (n = 962) of HCV patients presented with steatosis (+S) (higher rate in GT-3). Diabetes mellitus was more frequent in GT-1 patients. HCV patients without steatosis (-S) had a slightly higher rate of fibrosis progression (FP) over time (30.3%) in contrast to HCV patients +S (26%). This effect was mainly observed in GT-3 patients (34.4% vs. 20.6%). A larger decrease of ALT, AST and GGT from baseline to FU-1 (4–24 weeks after EOT) was found in HCV patients (without FP) +S compared to -S. HCV patients -S and with FP presented more often metabolic comorbidities with a significantly higher BMI (+0.58kg/m2) compared to patients -S without FP. This was particularly pronounced in patients with abnormal ALT. <h4>Conclusion</h4> Clinically diagnosed steatosis in HCV patients does not seem to contribute to significant FP in this unique cohort. The low prevalence of steatosis could reflect a lower awareness of fatty liver in HCV patients, as patients -S and with FP presented more metabolic risk factors.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203066/?tool=EBI |
| spellingShingle | Monika Rau Peter Buggisch Stefan Mauss Klaus H. W. Boeker Hartwig Klinker Tobias Müller Albrecht Stoehr Jörn M. Schattenberg Andreas Geier Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry PLoS ONE |
| title | Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry |
| title_full | Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry |
| title_fullStr | Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry |
| title_full_unstemmed | Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry |
| title_short | Prognostic impact of steatosis in the clinical course of chronic HCV infection—Results from the German Hepatitis C-Registry |
| title_sort | prognostic impact of steatosis in the clinical course of chronic hcv infection results from the german hepatitis c registry |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203066/?tool=EBI |
| work_keys_str_mv | AT monikarau prognosticimpactofsteatosisintheclinicalcourseofchronichcvinfectionresultsfromthegermanhepatitiscregistry AT peterbuggisch prognosticimpactofsteatosisintheclinicalcourseofchronichcvinfectionresultsfromthegermanhepatitiscregistry AT stefanmauss prognosticimpactofsteatosisintheclinicalcourseofchronichcvinfectionresultsfromthegermanhepatitiscregistry AT klaushwboeker prognosticimpactofsteatosisintheclinicalcourseofchronichcvinfectionresultsfromthegermanhepatitiscregistry AT hartwigklinker prognosticimpactofsteatosisintheclinicalcourseofchronichcvinfectionresultsfromthegermanhepatitiscregistry AT tobiasmuller prognosticimpactofsteatosisintheclinicalcourseofchronichcvinfectionresultsfromthegermanhepatitiscregistry AT albrechtstoehr prognosticimpactofsteatosisintheclinicalcourseofchronichcvinfectionresultsfromthegermanhepatitiscregistry AT jornmschattenberg prognosticimpactofsteatosisintheclinicalcourseofchronichcvinfectionresultsfromthegermanhepatitiscregistry AT andreasgeier prognosticimpactofsteatosisintheclinicalcourseofchronichcvinfectionresultsfromthegermanhepatitiscregistry |